Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sage Therapeutic Falls 4.27% on Heavy Volume: Watch For Potential Rebound

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $157.12 to a high of $165.50. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of...

SAGE : 153.46 (-4.83%)
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

--Collaboration supports Shionogi's vision of creating a more vigorous society by exploring the potential to provide relief from the psychological uncertainty of depression with a novel treatment paradigm...

SAGE : 153.46 (-4.83%)
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

--Collaboration supports Shionogi's vision of creating a more vigorous society by exploring the potential to provide relief from the psychological uncertainty of depression with a novel treatment paradigm...

SAGE : 153.46 (-4.83%)
Company News For Jun 13, 2018

Companies In The News are: TSLA,SAGE,RH,PLAY

PLAY : 51.60 (-1.58%)
TSLA : 333.63 (-3.99%)
RH : 151.35 (+1.61%)
SAGE : 153.46 (-4.83%)
Today's Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited...

SAGE : 153.46 (-4.83%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Sage Therapeutic (SAGE , RDUS , ALNY , ICPT , ADRO )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

RDUS : 30.54 (-1.71%)
ALNY : 104.20 (+1.47%)
SAGE : 153.46 (-4.83%)
Look for Shares of Sage Therapeutic to Potentially Pullback after Yesterday's 17.70% Rise

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $152.01 to a high of $173.92. Yesterday, the shares gained 17.7%, which took the trading range above the 3-day high...

SAGE : 153.46 (-4.83%)
Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics, Harris, and A-Mark Precious Metals -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy Partners, LP...

CQP : 37.18 (+2.57%)
ANTM : 244.82 (+0.72%)
HRS : 143.70 (+0.38%)
SAGE : 153.46 (-4.83%)
AMRK : 13.67 (-1.30%)
UNH : 254.37 (+0.98%)
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

--Previously completed placebo-controlled study in MDD considered as pivotal; initiation of one additional Phase 3 pivotal trial anticipated in 2H of 2018

SAGE : 153.46 (-4.83%)
Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 153.46 (-4.83%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 153.46 (-4.83%)
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression

--If approved, brexanolone IV would be the first and only medication indicated for the treatment of postpartum depression

SAGE : 153.46 (-4.83%)
Sage Therapeutics to Present at Bernstein's 34th Annual Strategic Decisions Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 153.46 (-4.83%)
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Style Box ETF report for VTWG

IWO : 210.14 (-0.77%)
VTWG : 152.63 (-0.75%)
GRUB : 106.98 (-3.17%)
SAGE : 153.46 (-4.83%)
VBK : 179.58 (-0.45%)
NKTR : 52.85 (-5.39%)
Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 153.46 (-4.83%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 153.46 (-4.83%)
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness

--Significant progress achieved in launch readiness preparations in anticipation of potential 1H 2019 brexanolone IV launch

SAGE : 153.46 (-4.83%)
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the...

SAGE : 153.46 (-4.83%)
Watch for Sage Therapeutic to Potentially Rebound After Falling 9.69% Yesterday

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $150.23 to a high of $168.53. Yesterday, the shares fell 9.7%, which took the trading range below the 3-day low of...

SAGE : 153.46 (-4.83%)
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Style Box ETF report for VTWG

IWO : 210.14 (-0.77%)
EXAS : 66.33 (-3.62%)
VTWG : 152.63 (-0.75%)
SAGE : 153.46 (-4.83%)
VBK : 179.58 (-0.45%)
NKTR : 52.85 (-5.39%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -2.19 , FTNT -0.81 , CAKE -2.16 , PLT -0.20 , AEO -0.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed Friday steady to fractionally mixed, as July was down 1.11% on the week. The USDA reported a private export sale of 131,300 MT of corn to Mexico this morning. The sale was broke down to 30,000 MT for delivery in 2017/18, with the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar